S&P 500   4,319.44 (-2.06%)
DOW   33,926.67 (-1.27%)
QQQ   344.13 (-2.60%)
AAPL   158.38 (-2.00%)
MSFT   286.96 (-3.18%)
FB   300.28 (-2.73%)
GOOGL   2,553.42 (-2.40%)
AMZN   2,790.81 (-3.46%)
TSLA   913.63 (-1.76%)
NVDA   222.80 (-4.67%)
BABA   118.79 (-1.31%)
NIO   23.56 (-5.27%)
AMD   110.93 (-4.81%)
CGC   7.10 (-4.05%)
MU   80.62 (-2.81%)
GE   89.91 (-7.22%)
T   26.08 (-0.99%)
F   19.88 (-2.50%)
DIS   134.44 (-2.20%)
AMC   15.96 (-4.09%)
PFE   51.85 (+0.60%)
ACB   4.07 (-5.79%)
BA   200.43 (-1.85%)
S&P 500   4,319.44 (-2.06%)
DOW   33,926.67 (-1.27%)
QQQ   344.13 (-2.60%)
AAPL   158.38 (-2.00%)
MSFT   286.96 (-3.18%)
FB   300.28 (-2.73%)
GOOGL   2,553.42 (-2.40%)
AMZN   2,790.81 (-3.46%)
TSLA   913.63 (-1.76%)
NVDA   222.80 (-4.67%)
BABA   118.79 (-1.31%)
NIO   23.56 (-5.27%)
AMD   110.93 (-4.81%)
CGC   7.10 (-4.05%)
MU   80.62 (-2.81%)
GE   89.91 (-7.22%)
T   26.08 (-0.99%)
F   19.88 (-2.50%)
DIS   134.44 (-2.20%)
AMC   15.96 (-4.09%)
PFE   51.85 (+0.60%)
ACB   4.07 (-5.79%)
BA   200.43 (-1.85%)
S&P 500   4,319.44 (-2.06%)
DOW   33,926.67 (-1.27%)
QQQ   344.13 (-2.60%)
AAPL   158.38 (-2.00%)
MSFT   286.96 (-3.18%)
FB   300.28 (-2.73%)
GOOGL   2,553.42 (-2.40%)
AMZN   2,790.81 (-3.46%)
TSLA   913.63 (-1.76%)
NVDA   222.80 (-4.67%)
BABA   118.79 (-1.31%)
NIO   23.56 (-5.27%)
AMD   110.93 (-4.81%)
CGC   7.10 (-4.05%)
MU   80.62 (-2.81%)
GE   89.91 (-7.22%)
T   26.08 (-0.99%)
F   19.88 (-2.50%)
DIS   134.44 (-2.20%)
AMC   15.96 (-4.09%)
PFE   51.85 (+0.60%)
ACB   4.07 (-5.79%)
BA   200.43 (-1.85%)
S&P 500   4,319.44 (-2.06%)
DOW   33,926.67 (-1.27%)
QQQ   344.13 (-2.60%)
AAPL   158.38 (-2.00%)
MSFT   286.96 (-3.18%)
FB   300.28 (-2.73%)
GOOGL   2,553.42 (-2.40%)
AMZN   2,790.81 (-3.46%)
TSLA   913.63 (-1.76%)
NVDA   222.80 (-4.67%)
BABA   118.79 (-1.31%)
NIO   23.56 (-5.27%)
AMD   110.93 (-4.81%)
CGC   7.10 (-4.05%)
MU   80.62 (-2.81%)
GE   89.91 (-7.22%)
T   26.08 (-0.99%)
F   19.88 (-2.50%)
DIS   134.44 (-2.20%)
AMC   15.96 (-4.09%)
PFE   51.85 (+0.60%)
ACB   4.07 (-5.79%)
BA   200.43 (-1.85%)
NASDAQ:CRNX

Crinetics Pharmaceuticals Stock Forecast, Price & News

$18.20
-1.38 (-7.05%)
(As of 01/25/2022 11:29 AM ET)
Add
Compare
Today's Range
$18.20
$19.01
50-Day Range
$18.97
$28.41
52-Week Range
$13.83
$28.95
Volume
3,546 shs
Average Volume
240,840 shs
Market Capitalization
$864.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.35
30 days | 90 days | 365 days | Advanced Chart
Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Crinetics Pharmaceuticals logo

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Headlines

Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Down to $20.93
January 24, 2022 |  americanbankingnews.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Gap Down to $24.01
January 18, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRNX
Fax
N/A
Employees
93
Year Founded
N/A

Sales & Book Value

Annual Sales
$70 thousand
Price / Sales
12,350.00
Book Value
$5.13 per share

Profitability

Net Income
$-73.81 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
43,985,000
Market Cap
$864.50 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/05/2021
Today
1/25/2022
Next Earnings (Estimated)
3/29/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.34 out of 5 stars

Medical Sector

245th out of 1,415 stocks

Pharmaceutical Preparations Industry

105th out of 683 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

Is Crinetics Pharmaceuticals a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals
or view top-rated stocks.

How has Crinetics Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRNX shares have increased by 17.4% and is now trading at $18.20.
View which stocks have been most impacted by COVID-19
.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Crinetics Pharmaceuticals
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced its earnings results on Friday, November, 5th. The company reported ($0.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.01.
View Crinetics Pharmaceuticals' earnings history
.

What price target have analysts set for CRNX?

6 equities research analysts have issued 1-year price targets for Crinetics Pharmaceuticals' shares. Their forecasts range from $28.00 to $45.00. On average, they expect Crinetics Pharmaceuticals' share price to reach $36.80 in the next year. This suggests a possible upside of 102.2% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:
  • Scott R. Struthers, President, Chief Executive Officer & Director
  • Jeff E Knight, Chief Operating Officer
  • Marc J. S. Wilson, Chief Financial Officer
  • Robert Flath, Finance Director
  • Stephen F. Betz, Chief Scientific Officer (LinkedIn Profile)

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $18.20.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals has a market capitalization of $864.50 million and generates $70 thousand in revenue each year. The company earns $-73.81 million in net income (profit) each year or ($2.78) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals employs 93 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

Where are Crinetics Pharmaceuticals' headquarters?

Crinetics Pharmaceuticals is headquartered at 10222 Barnes Canyon Road Building #2, San Diego CA, 92121.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at (858) 450-6464 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.